The ACR holds meetings with executive agencies, such as the FDA and CMS, to give rheumatology a strong voice in regulatory policymaking and to ensure that regulators have a full grasp of how regulatory oversight, or lack thereof, impacts rheumatologists and their patients. As such, we often reach out to members to take part in these meetings so their perspectives and expertise from the field can be heard. These meetings with regulators can strengthen the synergy we have on issues of agreement and develop a constructive dialog on issues of disagreement.
ACR/ARP members with concerns or issues related to FDA or CMS regulations, or who are interested in participating in a meeting with these agencies, should email the ACR’s advocacy team at [email protected]. We will continue to keep members fully informed on our discussions with these agencies, as well as on any regulations from them that may impact the practice of rheumatology.
